EGFR and neoplasm: Consistently, co-treating EGFR transgenic mouse lung tumour tissue-derived organoids with osimertinib, VX-509, and AICAR significantly inhibited tumour organoid initiation in 10 days (p < 0.05) (Fig. 6d).